Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer

Molecular Cancer

Review

Saikat Dewanjee¹  Saurabh Kumar Jha²  Niraj Kumar Jha³  Yuehua Li⁴  Zhe-Sheng Chen⁵  Ankush Kumar⁶  Tapan Behl⁷  Hailin Tang⁸  Feng Ye⁸ 

[1] Advanced Pharmacognosy Research Laboratory, Department of Pharmaceutical Technology, Jadavpur University, 700032, Kolkata, India;Department of Biotechnology, School of Engineering and Technology, Sharda University, Greater Noida, India;Department of Biotechnology Engineering and Food Technology, Chandigarh University, 140413, Mohali, India;Department of Biotechnology, School of Applied & Life Sciences (SALS), Uttaranchal University, 248007, Dehradun, India;Department of Biotechnology, School of Engineering and Technology, Sharda University, Greater Noida, India;School of Bioengineering & Biosciences, Lovely Professional University, 144411, Phagwara, India;Department of Medical Oncology, the First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, China;Institute of Pathogenic Biology, Hengyang Medical College, University of South China, Hengyang, China;Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John’s University, 11439, New York, USA;Pharmaceutical and Health Sciences, Career Point University, Hamirpur, Himachal Pradesh, India;School of Health Sciences and Technology, University of Petroleum and Energy Studies, Bidholi, Dehradun, Uttarakhand, India;State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, China;

关键词: Breast cancer;    Clinical trials;    Immune-checkpoint Inhibitors;    Immunotherapy;    Targeted therapies;   

DOI  :  10.1186/s12943-023-01805-y

 received in 2023-02-27, accepted in 2023-06-08,  发布年份 2023

来源: Springer

【 摘 要 】

Breast cancer is the second leading cause of death for women worldwide. The heterogeneity of this disease presents a big challenge in its therapeutic management. However, recent advances in molecular biology and immunology enable to develop highly targeted therapies for many forms of breast cancer. The primary objective of targeted therapy is to inhibit a specific target/molecule that supports tumor progression. Ak strain transforming, cyclin-dependent kinases, poly (ADP-ribose) polymerase, and different growth factors have emerged as potential therapeutic targets for specific breast cancer subtypes. Many targeted drugs are currently undergoing clinical trials, and some have already received the FDA approval as monotherapy or in combination with other drugs for the treatment of different forms of breast cancer. However, the targeted drugs have yet to achieve therapeutic promise against triple-negative breast cancer (TNBC). In this aspect, immune therapy has come up as a promising therapeutic approach specifically for TNBC patients. Different immunotherapeutic modalities including immune-checkpoint blockade, vaccination, and adoptive cell transfer have been extensively studied in the clinical setting of breast cancer, especially in TNBC patients. The FDA has already approved some immune-checkpoint blockers in combination with chemotherapeutic drugs to treat TNBC and several trials are ongoing. This review provides an overview of clinical developments and recent advancements in targeted therapies and immunotherapies for breast cancer treatment. The successes, challenges, and prospects were critically discussed to portray their profound prospects.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

12888_2023_4994_Article_IEq4.gif

12888_2023_4994_Article_IEq2.gif

Fig. 1

41116_2023_38_Article_IEq190.gif

Fig. 1

41116_2023_38_Article_IEq161.gif

41116_2023_38_Article_IEq347.gif

41116_2023_38_Article_IEq340.gif

41116_2023_38_Article_IEq339.gif

41116_2023_38_Article_IEq338.gif

41116_2023_38_Article_IEq327.gif

41116_2023_38_Article_IEq320.gif

41116_2023_38_Article_IEq314.gif

41116_2023_38_Article_IEq310.gif

41116_2023_38_Article_IEq297.gif